Severity
Low
FDA Drug recall · Reported January 22, 2014
Failed Impurities/Degradation:Specifications:Unknown degradant found during stability testing.
Novartis Consumer Health recalled Maximum Strength Comtrex Nighttime Cold & Cough, Acetaminophen 325mg ,Chlorpheniramine Ma… - a low-severity action.
Maximum Strength Comtrex Nighttime Cold & Cough, Acetaminophen 325mg ,Chlorpheniramine Ma… was recalled by Novartis Consumer Health in January 22, 2014. Reason: Failed Impurities/Degradation:Specifications:Unknown degradant found during stability testing.. Check the official notice for the remedy. Verify recall #D-739-2014 with the FDA Drug before acting.
The recall
Novartis Consumer Health issued this low-severity FDA Drug recall-Failed Impurities/Degradation:Specifications:Unknown degradant found during stability testing..
Sourced from official FDA Drug enforcement records. Verify recall #D-739-2014 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-739-2014) was formally reported on January 22, 2014, with the manufacturer initiating the action on May 15, 2013. It is classified under Low severity (Class III), with a current status of Terminated. Novartis Consumer Health is listed as the recalling firm, operating out of Lincoln, NE. Federal records list the affected scope as 32,256/24-caplet packages.
The documented reason for this recall is: Failed Impurities/Degradation:Specifications:Unknown degradant found during stability testing. Distribution data in the federal record shows the product reached: Distribution was made nationwide and foriegn distribution was made--Mexicio, Panama, Ecuador and Venezuela.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
32,256/24-caplet packages
Related Recalls
6
5 from same agency
Maximum Strength Comtrex Nighttime Cold & Cough, Acetaminophen 325mg ,Chlorpheniramine Maleate 2mg, Dextromethorphan HBR 10mg,Phenylephrine HCL 5mg, packaged in 24 coated caplets nighttime formula *includes antihistamine, Distributed by: Novartis Consumer Health, Inc., Parsippany, NJ 075054-0622, NDC 0067-2081-24.
Failed Impurities/Degradation:Specifications:Unknown degradant found during stability testing.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-739-2014 |
| Date reported | January 22, 2014 |
| Date initiated | May 15, 2013 |
| Recalling firm | Novartis Consumer Health |
| Firm location | Lincoln, NE |
| Affected scope | 32,256/24-caplet packages |
| Distribution | Distribution was made nationwide and foriegn distribution was made--Mexicio, Panama, Ecuador and Venezuela. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 22, 2014. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.